CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
2.600
-0.060 (-2.26%)
Jul 27, 2026, 2:25 PM EDT - Market open
CervoMed Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2.09 | 4.01 | 9.74 | 7.14 | - | - | |
Revenue Growth | -77.56% | -58.86% | 36.29% | - | - | - |
Gross Profit | 2.09 | 4.01 | 9.74 | 7.14 | - | - |
Selling, General & Admin | 11.08 | 10.48 | 9.17 | 6.52 | 2.14 | 7.45 |
Depreciation & Amortization Expenses | - | - | - | - | - | 0.09 |
Research & Development | 22.11 | 21.82 | 18.8 | 8.44 | 1.34 | 8.5 |
Other Operating Expenses | - | - | - | - | - | 8.64 |
Total Operating Expenses | 33.19 | 32.3 | 27.97 | 14.96 | 3.48 | 24.68 |
Operating Income | -31.1 | -28.29 | -18.23 | -7.81 | -3.48 | -24.68 |
Interest Income | 1.08 | 1.34 | 1.94 | 0.22 | 0.06 | 0.14 |
Interest Expense | - | - | - | - | 0 | - |
Other Non-Operating Income (Expense) | -0.43 | -0.01 | -0 | 5.42 | -2.39 | - |
Total Non-Operating Income (Expense) | 0.65 | 1.33 | 1.94 | 5.64 | -2.33 | 0.14 |
Pretax Income | -30.46 | -26.97 | -16.29 | -2.17 | -5.8 | -24.54 |
Provision for Income Taxes | - | - | - | - | - | -0.44 |
Net Income | -30.04 | -26.97 | -16.29 | -2.17 | -5.8 | -24.1 |
Net Income to Common | -30.04 | -26.97 | -16.29 | -2.17 | -5.8 | -24.1 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 9 | 9 | 8 | 3 | 1 | 1 |
Shares Outstanding (Diluted) | 9 | 9 | 8 | 3 | 1 | 1 |
Shares Change | 6.33% | 12.00% | 203.34% | 413.65% | -27.81% | - |
EPS (Basic) | -3.42 | -2.98 | -2.02 | -0.82 | -11.20 | -18.57 |
EPS (Diluted) | -3.42 | -2.98 | -2.02 | -0.82 | -11.20 | -18.57 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -27.57 | -23.45 | -16.53 | -7.45 | -2.57 | -14.5 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -2.98 | -2.59 | -2.05 | -2.80 | -4.97 | -20.20 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | - | - |
Operating Margin | -1488.86% | -706.22% | -187.18% | -109.35% | - | - |
Profit Margin | -1437.83% | -673.06% | -167.29% | -30.40% | - | - |
FCF Margin | -1319.95% | -585.30% | -169.76% | -104.27% | - | - |
EBITDA | -31.1 | -28.29 | -18.23 | -7.81 | -3.48 | -24.58 |
EBIT | -31.1 | -28.29 | -18.23 | -7.81 | -3.48 | -24.68 |
EBIT Margin | -1488.86% | -706.22% | -187.18% | -109.35% | - | - |
Effective Tax Rate | - | 0.00% | 0.00% | 0.00% | 0.00% | 1.81% |